Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

• Status: Unknown status
• Trial end date: 2021-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine which treatment is more effective and safer for the patients in COPD C group with bronchiectasis.The research results will help guide physicians to select appropriate individualized treatment and hopefully provide some evidence-based medicine proofs for revising guide.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
• Treatments: Bromides; Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate; Tiotropium Bromide

Criteria

Inclusion Criteria:

• Patients are suitable for inclusion in the study when they are 18 years or older diagnosed with COPD C group and bronchiectasis.

Exclusion Criteria:

• active tuberculosis

• severe respiratory disease (such as Lung cancer, ARDS, pulmonary encephalopathy, respiratory failure)

• uncontrollable diabetes

• hypersensitivity to any components of ICS/LABA or LAMA.